Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE ... Life ...

Insilico Medicine pulls back the curtain on developmental timelines, highlighting a ~13 month average timeline to reach developmental candidate (DC) nomination across 22 programs. Insilico’s QPCTL ...

The real estate investment trust focused on UK life sciences properties let 17,200 square feet at building 1020 to 42 Technology Ltd under a 10-year lease. 42T pays GBP25.50 per square foot in rent, ...

Ruby Jackson speaks to the psychiatrist researching the therapeutic potential of psychedelics ...

Plant-based medicine advocates haven't given up their efforts to see that therapeutic method take root. Question 4, defeated on the state ballot in November, would have legalized some psychedelics for ...

With the readout of UNVEIL-IT® Phase 2, which evaluates VS-01, also targeted in the second half of 2025, up to 4 clinical datasets are expected to be released by GENFIT before the end of this year ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...